|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 11/06/07 Independence Resources PLC 8-K:7,9 11/06/07 2:3.2M RR Donnelley/FA |
Document/Exhibit Description Pages Size
1: 8-K Current Report HTML 17K
2: EX-10.1 Senetek Plc Presentation at the Rodman and Renshaw HTML 22K
Conference
| Senetek PLC Presentation at the Rodman and Renshaw Conference |
Exhibit 10.1
Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
November 5 – 7, 2007 New York, New York
This presentation contains statements that may be considered ‘forward looking statements’ within the meaning of the Private Securities Litigation Reform Act, including those indicating the financial outlook and projections that might imply commercial potential and successful evaluation and development of new compounds. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward- looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
A Specialty Life Sciences Company Engaged in the Study of Senescence, the Science of Aging with an Initial Focus on Skincare and Dermatological Therapeutics
Headed by Professor Brian Clark, Ph.D., ScD., Senetek PLC’s Chief Scientist
? Achievements:
Discovery of the Initiation Codon for Protein Synthesis, 1965/1966
First Crystallization of tRNA, 1968
Determination of the First Structure of a GTP-Binding Protein, 1985
Structural Determination of the Ternary Complex, 1995
Past President of the International Union of Biochemistry and Molecular Biology, 1997
Head, European Chinese Biotechnology Transfer Task Force
? Publications:
Over 200 Papers
| 5 |
|
Books |
World Renowned Scientific Advisory Board
? Sir John Walker, Ph.D., F.R.S., Scientific Advisor
Nobel Prize in Chemistry, 1997
Thought Leader in Nutrition & Aging
Expert on Mitochondria
? Professor Claudio Francheschi, M.D., EU Project Partner & Science Advisor
Professor, University of Bologna and Scientific Director of the Italian National Research Center on Aging-Department of Gerontological Studies, Bologna, Italy
Expert on Inflammation and the Genetics of Aging
? Dr. Gerald Weinstein, M.D.
University of California Department of Dermatology, Irvine (Emeritus)
World Renowned Expert on Photo Damaged Skin and Psoriasis
Institute of Experimental Botany—Czech Republic
Cooperative Research Agreement to Study Plant Physiology, Genetics and Biotechnology
Institute of Bioorganic Chemistry—Polish Academy of Sciences
Polish State Scientific Institution
PROTEOMAGE—European Integrated Project
Consortium of Leading European Researchers of Healthy Aging
National Hellenic Research Foundation of the Foundation of Biological Research and Biotechnology
University of California at Irvine—Department of Dermatology
Comprehensive Consulting, Pre-Clinical and Clinical Testing Services for Pharmaceutical and Cosmetic Compounds
Over 2000 Patented and Patent Applied for Compounds
Patent Applied for Suppression of Brain Tumors
Currently in Human Clinical Trials in Europe
Extraordinary Results for example individual diagnosed with grade 3 glioblastoma multiforme (average life expectancy from diagnosis equals 8 months) treated and alive 24 months post diagnosis
1999 Launched Kinerase® Through ICN/Valeant Pharmaceuticals, the Leading Antiaging Product in the North American Physician Market
2004 Licensed Invicorp® to Ardana BioSciences for the European Market
2006 Licensed Invicorp® to Plethora Solutions Holdings Ltd. For the North American Market
2006 Transferred Reliaject® to Ranbaxy Pharmaceuticals for Milestone Payments and Royalties for 15 Years from the Date of First Commercial Sale
2006 Entered into Agreement with Covance Antibody Services for the Distribution of Diagnostic Monoclonal Antibodies
2007 Marketing Collaboration for Pyratine-6™ with Triax Pharmaceuticals
“ Strong I ndustry Relationships”
No Debt
Cash on Hand at $20 Million
Minimum Guaranteed Revenue Stream of $12 Million in 2008
Total 2008 2009 Revenue $ 26,762* $ 13,397 $ 21,891 Gross Margin 25,270 10,492 12,872
Operating Income 20,795 1,634 5,017
Net Income 18,437 1,549 3,748 EBITDA 17,851 2,262 5,645
| * |
|
Includes Kinetin Monetization of $24 Million |
Pyratine-6™
4HBAP
Baseline Week 12
Photo Damaged Skin
Subject 11—Right
Baseline
Week 12
Photo Damaged Skin
Subject 26—Right
Baseline Week 12
Acne Rosacea
Subject 19
Baseline
Week 12
Photo Damaged Skin
Subject 16—Left
Baseline Week 12
Acne Vulgaris/Skin Lightening
Subject 32
Skin Moisture Content 4HBAP
Acne
(Investigator Assessment) 4HBAP
In Transition
Yesterday: Outlicensing
Today: Marketing Collaborations
Higher Revenues
Corporate and Brand Recognition
Rich Portfolio of Technology
World Class Science
Proven Commercial Successes
Financially Stable